Individual fracture risk and the cost-effectiveness of bisphosphonates in patients using oral glucocorticoids.

Tjeerd Van Staa; T P van Staa; P Geusens; B Zhang; H G M Leufkens; A Boonen; C Cooper

doi:10.1093/rheumatology/kel249

Individual fracture risk and the cost-effectiveness of bisphosphonates in patients using oral glucocorticoids.

Tjeerd Van Staa, T P van Staa, P Geusens, B Zhang, H G M Leufkens, A Boonen, C Cooper

Research output: Contribution to journal › Article › peer-review

Abstract

OBJECTIVES: There are few data on the cost-effectiveness of bisphosphonates with oral glucocorticoids (GCs). An individual patient-based pharmaco-economic model was developed. METHODS: Data were obtained from a cohort of oral GC users aged 40+ (n = 190 000) in the UK General Practice Research Database. Individualized fracture and mortality risks were calculated specific for age, sex, daily and cumulative GC dose, indication and other clinical risk factors. UK costs of medication and direct costs of fracture were obtained from National Institute for Clinical Excellence and used to estimate costs per quality-adjusted life-year (QALY) gained and fracture prevented for bisphosphonates in patients treated for 5 yrs with GCs. RESULTS: With the use of 5 mg GCs daily, the cost per one QALY gained with bisphosphonates was 41k UK pounds (95% confidence intervals 22-72k) in women aged

Original language	English
Journal	Rheumatology (Oxford, England)
Volume	46
Issue number	3
DOIs	https://doi.org/10.1093/rheumatology/kel249
Publication status	Published - Mar 2007

Access to Document

10.1093/rheumatology/kel249

Cite this

@article{ed6f84ba9d074bfc8ebd86359f4b6341,

title = "Individual fracture risk and the cost-effectiveness of bisphosphonates in patients using oral glucocorticoids.",

abstract = "OBJECTIVES: There are few data on the cost-effectiveness of bisphosphonates with oral glucocorticoids (GCs). An individual patient-based pharmaco-economic model was developed. METHODS: Data were obtained from a cohort of oral GC users aged 40+ (n = 190 000) in the UK General Practice Research Database. Individualized fracture and mortality risks were calculated specific for age, sex, daily and cumulative GC dose, indication and other clinical risk factors. UK costs of medication and direct costs of fracture were obtained from National Institute for Clinical Excellence and used to estimate costs per quality-adjusted life-year (QALY) gained and fracture prevented for bisphosphonates in patients treated for 5 yrs with GCs. RESULTS: With the use of 5 mg GCs daily, the cost per one QALY gained with bisphosphonates was 41k UK pounds (95% confidence intervals 22-72k) in women aged",

author = "{Van Staa}, Tjeerd and {van Staa}, {T P} and P Geusens and B Zhang and Leufkens, {H G M} and A Boonen and C Cooper",

note = "G0400491, Medical Research Council, United KingdomMC_UP_A620_1014, Medical Research Council, United Kingdom",

year = "2007",

month = mar,

doi = "10.1093/rheumatology/kel249",

language = "English",

volume = "46",

journal = "Rheumatology (Oxford, England)",

issn = "1462-0332",

publisher = "Oxford University Press",

number = "3",

}

TY - JOUR

T1 - Individual fracture risk and the cost-effectiveness of bisphosphonates in patients using oral glucocorticoids.

AU - Van Staa, Tjeerd

AU - van Staa, T P

AU - Geusens, P

AU - Zhang, B

AU - Leufkens, H G M

AU - Boonen, A

AU - Cooper, C

N1 - G0400491, Medical Research Council, United KingdomMC_UP_A620_1014, Medical Research Council, United Kingdom

PY - 2007/3

Y1 - 2007/3

N2 - OBJECTIVES: There are few data on the cost-effectiveness of bisphosphonates with oral glucocorticoids (GCs). An individual patient-based pharmaco-economic model was developed. METHODS: Data were obtained from a cohort of oral GC users aged 40+ (n = 190 000) in the UK General Practice Research Database. Individualized fracture and mortality risks were calculated specific for age, sex, daily and cumulative GC dose, indication and other clinical risk factors. UK costs of medication and direct costs of fracture were obtained from National Institute for Clinical Excellence and used to estimate costs per quality-adjusted life-year (QALY) gained and fracture prevented for bisphosphonates in patients treated for 5 yrs with GCs. RESULTS: With the use of 5 mg GCs daily, the cost per one QALY gained with bisphosphonates was 41k UK pounds (95% confidence intervals 22-72k) in women aged

AB - OBJECTIVES: There are few data on the cost-effectiveness of bisphosphonates with oral glucocorticoids (GCs). An individual patient-based pharmaco-economic model was developed. METHODS: Data were obtained from a cohort of oral GC users aged 40+ (n = 190 000) in the UK General Practice Research Database. Individualized fracture and mortality risks were calculated specific for age, sex, daily and cumulative GC dose, indication and other clinical risk factors. UK costs of medication and direct costs of fracture were obtained from National Institute for Clinical Excellence and used to estimate costs per quality-adjusted life-year (QALY) gained and fracture prevented for bisphosphonates in patients treated for 5 yrs with GCs. RESULTS: With the use of 5 mg GCs daily, the cost per one QALY gained with bisphosphonates was 41k UK pounds (95% confidence intervals 22-72k) in women aged

U2 - 10.1093/rheumatology/kel249

DO - 10.1093/rheumatology/kel249

M3 - Article

C2 - 16899499

SN - 1462-0332

VL - 46

JO - Rheumatology (Oxford, England)

JF - Rheumatology (Oxford, England)

IS - 3

ER -

Individual fracture risk and the cost-effectiveness of bisphosphonates in patients using oral glucocorticoids.

Abstract

Access to Document

Fingerprint

Cite this